Enzalutamide: IQWiG assessed data subsequently submitted by the manufacturer
Enzalutamide (trade name: Xtandi) has been approved since June 2013 for men with metastatic prostate cancer in whom the commonly used hormone blockade is no longer effective and who have already been treated with the cytostatic ...
Feb 21, 2014
0
0